Journal of Microbiology, Immunology and Infection, 2022 Background: Imipenem-relebactam is a new β-lactam and β-lactamase inhibitor combination to treat carbapenem-resistant gram-negative bacteria infections. However, difference in carbapenem resistant mechanisms existed with geographic variations. Objective:
I-Ling Lin +2 more
exaly +5 more sources
Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy [PDF]
Antibiotics, 2021 (1) Purpose of this study: determination of adsorption and transmembrane clearances (CLTM) of imipenem and relebactam in ex vivo continuous hemofiltration (CH) and continuous hemodialysis (CHD) models.
, Lenár Yessayan, Soo Min Jang
exaly +5 more sources
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam [PDF]
International Journal of Infectious Diseases, 2019 Objectives: Relebactam is a small molecule β-lactamase inhibitor under clinical investigation for use as a fixed-dose combination with imipenem/cilastatin.
Katherine Young, Pratik Bhagunde
exaly +5 more sources
Antimicrobial activity of ceftolozane/tazobactam, imipenem/relebactam, and comparators against Gram-negative pathogens collected in Arabian Gulf countries: SMART 2020–2024 [PDF]
Frontiers in Cellular and Infection MicrobiologyObjectivesTo investigate the in vitro susceptibility of recent clinical Enterobacterales and Pseudomonas aeruginosa isolates collected in the Arabian Gulf region to ceftolozane/tazobactam, imipenem/relebactam, and comparator antimicrobial agents ...
Mark G. Wise +5 more
doaj +2 more sources
Microbiology Spectrum, 2022 Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (
JOSÉ Melo Cristino +2 more
exaly +3 more sources
Current Therapeutic Research: Background: Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from Klebsiella pneumoniae.
Davood Mansury
exaly +3 more sources
In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Mycobacterium abscessus Complex Isolates [PDF]
AntibioticsBackground and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many
Alejandro Seoane-Estévez +12 more
doaj +2 more sources
Development of a novel LC-MS/MS method for concurrent determination of imipenem, relebactam, and cilastatin in human serum, urine and peritoneal drainage fluid [PDF]
BMC ChemistryWith the global spread of antimicrobial resistance (AMR), infections caused by multidrug-resistant bacteria have become a major challenge in clinical treatment.
Xiaoyu Yang +12 more
doaj +2 more sources
Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports [PDF]
Journal of Blood MedicineDao-Xing Deng,* Ting Wang,* Hui Sun,* Jun Kong, Yuan-Yuan Zhang, Le-Qing Cao, Xiao-Dong Mo Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center
Deng DX +6 more
doaj +2 more sources
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
Journal of Global Antimicrobial ResistanceWe assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support.
Jae Min +2 more
exaly +3 more sources